It’s Time to
Overcome Cancer Progression and Metastasis
MetaMol Theranostics is pioneering a new frontier in oncology by developing breakthrough diagnostic tools and anti-metastasis therapies rooted in over two decades of research into the cancer-specific molecule Osteopontin-c (OPNc). Our mission is to empower physicians with precise, individualized insights into breast cancer risk and to revolutionize treatment for patients with advanced disease.
It’s Time to Overcome Cancer Progression and Metastasis
MetaMol Theranostics is pioneering a new frontier in oncology by developing breakthrough diagnostic tools and anti-metastasis therapies rooted in over two decades of research into the cancer-specific molecule Osteopontin-c (OPNc). Our mission is to empower physicians with precise, individualized insights into breast cancer risk and to revolutionize treatment for patients with advanced disease
It’s Time to Overcome Cancer Progression and Metastasis
MetaMol Theranostics is pioneering a new frontier in oncology by developing breakthrough diagnostic tools and anti-metastasis therapies rooted in over two decades of research into the cancer-specific molecule Osteopontin-c (OPNc). Our mission is to empower physicians with precise, individualized insights into breast cancer risk and to revolutionize treatment for patients with advanced disease
It’s Time to Overcome Cancer Progression and Metastasis
MetaMol Theranostics is pioneering a new frontier in oncology by developing breakthrough diagnostic tools and anti-metastasis therapies rooted in over two decades of research into the cancer-specific molecule Osteopontin-c (OPNc). Our mission is to empower physicians with precise, individualized insights into breast cancer risk and to revolutionize treatment for patients with advanced disease
It's Time to Deafeat Cancer Progression & Metastasis
MetaMol Theranostics is developing an innovative approach to cancer, which seeks to provide patients and clinicians with deeper insight at the time of diagnosis and to deliver targeted antibody therapies designed to halt metastasis. By focusing on hOPNc, a key driver of cancer progression, we aim to prevent the spread of early disease and transform outcomes for patients facing advanced, metastatic cancer.